Influence of respiratory syncytial virus F glycoprotein conformation on induction of protective immune responses

Journal of Virology

Volumn 90, Issue 11, 2016, Pages 5485-5498

  Palomo, Concepción ^a,b   Mas, Vicente ^a,b   Thom, Michelle ^c   Vázquez, Mónica ^a,b   Cano, Olga ^a,b   Terrón, María C ^a   Luque, Daniel ^a   Taylor, Geraldine ^c   Melero, José A ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN RESPIRATORY SYNCYTIAL VIRUS F GLYCOPROTEIN; HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN; VIRUS VACCINE; CPG-OLIGONUCLEOTIDE; EPITOPE; F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; OLIGODEOXYRIBONUCLEOTIDE; RECOMBINANT PROTEIN; VIRUS FUSION PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SINGLE DRUG DOSE; VACCINE PRODUCTION; VIRUS LOAD; VIRUS NEUTRALIZATION; WEIGHT REDUCTION; ANIMAL; BLOOD; CHEMISTRY; DOSE RESPONSE; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; LUNG; PATHOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VACCINE IMMUNOGENICITY; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPITOPES; FEMALE; HUMANS; IMMUNIZATION; IMMUNOGENICITY, VACCINE; LUNG; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL FUSION PROTEINS;

EID: 84971459876     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00338-16     Document Type: Article

References (54)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555. http://dx.doi.org/10.1016/S0140-6736(10)60206-1.
2. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:422-434.
3. Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, Rodriguez WJ, Chanock RM. 1986. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 24:197-202.
4. Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, Lirman DD, Rabold R, Hoffman SJ, Karp CL, Kleeberger SR, Wills-Karp M, Karron RA. 2002. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 196:859-865. http://dx.doi.org/10.1084/jem.20020781.
5. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15:34-41. http://dx.doi.org/10.1038/nm.1894.
6. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. 1993. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 151:2032-2040.
7. Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, O'Shea AF, Gruber WC, Murphy BR. 2007. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 25:7372-7378. http://dx.doi.org/10.1016/j.vaccine.2007.08.014.
8. Morrison TG, Walsh EE. 2013. Subunit and virus-like particle vaccine approaches for respiratory syncytial virus. Curr Top Microbiol Immunol 372:285-306. http://dx.doi.org/10.1007/978-3-642-38919-1_14.
9. Graham BS, Davis TH, Tang YW, Gruber WC. 1993. Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virus-specific immune serum. Pediatr Res 34:167-172. http://dx.doi.org/10.1203/00006450-199308000-00013.
10. Prince GA, Horswood RL, Chanock RM. 1985. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 55:517-520.
11. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, Tristram DA, Siber GR, Prince GA, Van Raden M, Hemming VG, Respiratory Syncytial Virus Immune Globulin Study Group. 1993. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 329:1524-1530.
12. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176:1215-1224. http://dx.doi.org/10.1086/514115.
13. Hall CB, Walsh EE, Long CE, Schnabel KC. 1991. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163: 693-698. http://dx.doi.org/10.1093/infdis/163.4.693.
14. Glezen WP, Taber LH, Frank AL, Kasel JA. 1986. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140:543-546.
15. Falsey AR, Walsh EE. 1998. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 177:463-466. http://dx.doi.org/10.1086/517376.
16. Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 162: 80-99. http://dx.doi.org/10.1016/j.virusres.2011.09.020.
17. Levine S, Klaiber-Franco R, Paradiso PR. 1987. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J Gen Virol 68(Part 9):2521-2524.
18. Hallak LK, Collins PL, Knudson W, Peeples ME. 2000. Iduronic acidcontaining glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology 271:264-275. http://dx.doi.org/10.1006/viro.2000.0293.
19. Hallak LK, Spillmann D, Collins PL, Peeples ME. 2000. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol 74:10508-10513. http://dx.doi.org/10.1128/JVI.74.22.10508-10513.2000.
20. Martinez I, Melero JA. 2000. Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. J Gen Virol 81:2715-2722. http://dx.doi.org/10.1099/0022-1317-81-11-2715.
21. Melero JA, Mas V. 2015. The Pneumovirinae fusion (F) protein: a common target for vaccines and antivirals. Virus Res 209:128-135. http://dx.doi.org/10.1016/j.virusres.2015.02.024.
22. Connors M, Collins PL, Firestone CY, Murphy BR. 1991. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol 65:1634-1637.
23. Stott EJ, Taylor G, Ball LA, Anderson K, Young KK, King AM, Wertz GW. 1987. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol 61:3855-3861.
24. Olmsted RA, Elango N, Prince GA, Murphy BR, Johnson PR, Moss B, Chanock RM, Collins PL. 1986. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A 83:7462-7466. http://dx.doi.org/10.1073/pnas.83.19.7462.
25. Gonzalez-Reyes L, Ruiz-Arguello MB, Garcia-Barreno B, Calder L, Lopez JA, Albar JP, Skehel JJ, Wiley DC, Melero JA. 2001. Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci U S A 98:9859-9864. http://dx.doi.org/10.1073/pnas.151098198.
26. Lamb RA. 1993. Paramyxovirus fusion: a hypothesis for changes. Virology 197:1-11. http://dx.doi.org/10.1006/viro.1993.1561.
27. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A. 2011. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 108: 9619-9624. http://dx.doi.org/10.1073/pnas.1106536108.
28. McLellan JS, Yang Y, Graham BS, Kwong PD. 2011. Structure of the respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85:7788-7796. http://dx.doi.org/10.1128/JVI.00555-11.
29. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS. 2013. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340:1113-1117. http://dx.doi.org/10.1126/science.1234914.
30. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GY, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko SY, Todd JP, Rao S, Graham BS, Kwong PD. 2013. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342:592-598. http://dx.doi.org/10.1126/science.1243283.
31. Stewart-Jones GB, Thomas PV, Chen M, Druz A, Joyce MG, Kong WP, Sastry M, Soto C, Yang Y, Zhang B, Chen L, Chuang GY, Georgiev IS, McLellan JS, Srivatsan S, Zhou T, Baxa U, Mascola JR, Graham BS, Kwong PD. 2015. A cysteine zipper stabilizes a pre-fusion F glycoprotein vaccine for respiratory syncytial virus. PLoS One 10:e0128779. http://dx.doi.org/10.1371/journal.pone.0128779.
32. Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJ, Widjojoatmodjo MN, Zahn R, Schuitemaker H, McLellan JS, Langedijk JP. 2015. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun 6:8143. http://dx.doi.org/10.1038/ncomms9143.
33. Sastre P, Melero JA, Garcia-Barreno B, Palomo C. 2005. Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation. J Med Virol 76:248-255. http://dx.doi.org/10.1002/jmv.20349.
34. Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D, Terron MC, Melero JA, Palomo C. 2012. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A 109:3089-3094. http://dx.doi.org/10.1073/pnas.1115941109.
35. Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, Kumar A, Yassine HM, Moin SM, Killikelly AM, Chuang GY, Druz A, Georgiev IS, Rundlet EJ, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Nason MC, Capella C, Peeples ME, Ledgerwood JE, McLellan JS, Kwong PD, Graham BS. 2015. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 7:309ra162. http://dx.doi.org/10.1126/scitranslmed.aac4241.
36. Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CM, Lukens MV, van Bleek GM, Widjojoatmodjo MN, Bogers WM, Mei H, Radbruch A, Scheeren FA, Spits H, Beaumont T. 2010. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med 16:123-128. http://dx.doi.org/10.1038/nm.2071.
37. Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, Guarino B, Silacci C, Marcandalli J, Marsland BJ, Piralla A, Percivalle E, Sallusto F, Baldanti F, Lanzavecchia A. 2013. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501:439-443. http://dx.doi.org/10.1038/nature12442.
38. Gilman MS, Moin SM, Mas V, Chen M, Patel NK, Kramer K, Zhu Q, Kabeche SC, Kumar A, Palomo C, Beaumont T, Baxa U, Ulbrandt ND, Melero JA, Graham BS, McLellan JS. 2015. Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathog 11:e1005035. http://dx.doi.org/10.1371/journal.ppat.1005035.
39. Swanson KA, Balabanis K, Xie Y, Aggarwal Y, Palomo C, Mas V, Metrick C, Yang H, Shaw CA, Melero JA, Dormitzer PR, Carfi A. 2014. A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes. J Virol 88:11802-11810. http://dx.doi.org/10.1128/JVI.01225-14.
40. Bembridge GP, Lopez JA, Cook R, Melero JA, Taylor G. 1998. Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon. J Virol 72:4080-4087.
41. Calder LJ, Gonzalez-Reyes L, Garcia-Barreno B, Wharton SA, Skehel JJ, Wiley DC, Melero JA. 2000. Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 271:122-131. http://dx.doi.org/10.1006/viro.2000.0279.
42. Ruiz-Arguello MB, Martin D, Wharton SA, Calder LJ, Martin SR, Cano O, Calero M, Garcia-Barreno B, Skehel JJ, Melero JA. 2004. Thermostability of the human respiratory syncytial virus fusion protein before and after activation: implications for the membrane-fusion mechanism. J Gen Virol 85:3677-3687. http://dx.doi.org/10.1099/vir.0.80318-0.
43. Martin D, Calder LJ, Garcia-Barreno B, Skehel JJ, Melero JA. 2006. Sequence elements of the fusion peptide of human respiratory syncytial virus fusion protein required for activity. J Gen Virol 87:1649-1658. http://dx.doi.org/10.1099/vir.0.81715-0.
44. Anderson LJ, Bingham P, Hierholzer JC. 1988. Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol 62:4232-4238.
45. Magro M, Andreu D, Gomez-Puertas P, Melero JA, Palomo C. 2010. Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein. J Virol 84:7970-7982. http://dx.doi.org/10.1128/JVI.00447-10.
46. Martinez I, Dopazo J, Melero JA. 1997. Antigenic structure of the human respiratory syncytial virusGglycoprotein and relevance of hypermutation events for the generation of antigenic variants. J Gen Virol 78(Part 10): 2419-2429.
47. Garcia-Barreno B, Palomo C, Penas C, Delgado T, Perez-Brena P, Melero JA. 1989. Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J Virol 63:925-932.
48. Wu SJ, Schmidt A, Beil EJ, Day ND, Branigan PJ, Liu C, Gutshall LL, Palomo C, Furze J, Taylor G, Melero JA, Tsui P, Del Vecchio AM, Kruszynski M. 2007. Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches. J Gen Virol 88:2719-2723. http://dx.doi.org/10.1099/vir.0.82753-0.
49. Begona Ruiz-Arguello M, Gonzalez-Reyes L, Calder LJ, Palomo C, Martin D, Saiz MJ, Garcia-Barreno B, Skehel JJ, Melero JA. 2002. Effect of proteolytic processing at two distinct sites on shape and aggregation of an anchorless fusion protein ofhumanrespiratory syncytial virus and fate of the intervening segment. Virology 298:317-326. http://dx.doi.org/10.1006/viro.2002.1497.
50. Meier S, Guthe S, Kiefhaber T, Grzesiek S. 2004. Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable beta-hairpin: atomic details of trimer dissociation and local beta-hairpin stability from residual dipolar couplings. J Mol Biol 344:1051-1069. http://dx.doi.org/10.1016/j.jmb.2004.09.079.
51. Graham BS, Anderson LJ. 2013. Challenges and opportunities for respiratory syncytial virus vaccines. Curr Top Microbiol Immunol 372:391-404. http://dx.doi.org/10.1007/978-3-642-38919-1_20.
52. McGinnes Cullen L, Schmidt MR, Kenward SA, Woodland RT, Morrison TG. 2015. Murine immune responses to virus-like particleassociated pre-and postfusion forms of the respiratory syncytial virus F protein. J Virol 89:6835-6847. http://dx.doi.org/10.1128/JVI.00384-15.
53. Prince GA, Mond JJ, Porter DD, Yim KC, Lan SJ, Klinman DM. 2003. Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J. Virol 77:13156-13160. http://dx.doi.org/10.1128/JVI.77.24.13156-13160.2003.
54. Garlapati S, Garg R, Brownlie R, Latimer L, Simko E, Hancock RE, Babiuk LA, Gerdts V, Potter A, Drunen Littel-van den Hurk S. 2012. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. Vaccine 30:5206-5214. http://dx.doi.org/10.1016/j.vaccine.2012.06.011.